| Typicality: | 0.389 |
| Saliency: | 0.227 |
| in the biopharmaceutical industry | 7 | location |
| mainly | 3 | degree |
| growth → increase → r&d expenditure | 7 |
| growth → be driven by → increasing r&d spending | 3 |
| negative | neutral | positive |
| 0.003 | 0.259 | 0.738 |
| Raw frequency | 10 |
| Normalized frequency | 0.227 |
| Modifier score | 0.900 |
| Perplexity | 175.096 |